The beneficial effect of some nutrients in human health is a key driving factor for the growth of the business of dietary supplements and nutraceutical products worldwide. Astaxanthin and Omega-3 are common nutraceuticals recommended to prevent oxidative damages and ageing effects. Astaxanthin (ASX) is a natural pink color carotenoid primarily occurring in marine organisms (microalgae, salmon, trout, krill, shrimp, crayfish, and crustaceans), in the feathers of birds (quail, flamingo, and storks) as well as in propolis. ASX is an antioxidant molecule with protection role against free radicals, that are responsible for many diseases and ageing. It is characterized by the highest antioxidant activity with respect to other active compounds. Omega-3 (n-3) are long chain fatty acids, and essential nutrients for vertebrates. In humans, they are required to maintain cell membranes, brain functions, and the transmission of nerve impulses under normal conditions. Omega-3 also plays a key role in the processes of transfer of oxygen to blood plasma, hemoglobin synthesis, and cell division.
As of today, the global supply from all the traditional sources of astaxanthin and omega-3 fatty acids is insufficient to satisfy the market demand, especially regarding human nutrition.
The ASTAOMEGA ERC-PoC project was focused to develop innovative, low cost and high productive strategy can be proposed for simultaneous Astaxanthin and Omega-3 production in the robust and fast-growing marine microalgae species Nannochloropsis gaditana. During the ERC-PoC-ASTOMEGA the production of astaxanthin and EPA in the selected N- gaditana strain was optimized and scaled to demonstration stage with industrial partner. In parallel the IPR strategy was developed and a detailed business plan prepared. According to the business plan the ASTAOMEGA solution allow to yield yearly revenues in the first five years of operation in the 575.000-975.000€ range. The research team is now discussing with several industrial partners and investor in order to prepare the best strategy to exit in the market with production planned to start in January 2021.
